Oki Toshiya, Ishii Sachi, Furukawa Koya, Shono Aiko, Akazawa Manabu
Department of Public Health and Epidemiology, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo, 204-8588, Japan.
Department of Pharmacy, IMS Miyoshi General Hospital, 974-3 Fujikubo, Miyoshi-machi, Iruma-gun, Saitama, 354-0041, Japan.
J Pharm Health Care Sci. 2021 Dec 6;7(1):47. doi: 10.1186/s40780-021-00232-9.
Clinical pharmacists play a role in limiting the disadvantages of pharmacotherapy for patients by detecting and resolving drug-related problems (DRPs) through medication reviews. Although their contributions to patient care have been analyzed and understood in various countries, the role of Japanese clinical pharmacists in this context remains to be clearly elucidated. Thus, in this study, we aimed to elucidate the detection of DRPs by clinical pharmacists and determine the potential impact of pharmacist interventions in Japan.
This study was conducted in a 273-bed hospital and targeted hospitalized patients over a period of 6 months. DRPs detected by clinical pharmacists during the study period were investigated and classified into 10 types. Furthermore, medications were categorized according to the Anatomical Therapeutic Chemical classification. A review committee consisting of two pharmacists independently reviewed the pharmacist interventions on a six-point scale (extremely significant, very significant, significant, somewhat significant, no significance, adverse significance) according to the potential impact on patient care.
During the study period, 1711 patients (mean age: 71.2 years, 54.1% male) were included, and 2149 DRPs were detected (1.26 DRPs/patient). Pharmacists intervened in all the DRPs detected. The most common DRP was supratherapeutic dosage (19.3%), followed by untreated indication (18.1%). The most common medication classification causing DRPs was "Antiinfectives for Systemic Use" (25.1%), followed by "Alimentary Tract and Metabolism" (19.9%). Most of the pharmacist interventions (99.6%) were rated "somewhat significant" or more significant, of which 1.1% were rated "extremely significant," and none were rated as "adverse significance."
Our results show that in Japan, as in other countries, clinical pharmacists detect and resolve DRPs in hospitalized patients through medication review. Our findings also show that clinical pharmacists have a positive impact on patient care and suggest the need for their involvement.
临床药师通过药物治疗回顾来发现并解决药物相关问题(DRP),从而在减少患者药物治疗弊端方面发挥作用。尽管各国已对他们在患者护理方面的贡献进行了分析和了解,但日本临床药师在此方面的作用仍有待明确阐释。因此,在本研究中,我们旨在阐明临床药师对DRP的发现情况,并确定药师干预在日本所产生的潜在影响。
本研究在一家拥有273张床位的医院开展,以住院患者为研究对象,为期6个月。对研究期间临床药师发现的DRP进行调查,并分为10种类型。此外,药物按照解剖学治疗学化学分类法进行归类。由两名药师组成的评审委员会根据对患者护理的潜在影响,对药师的干预措施进行六点评分(极其显著、非常显著、显著、有些显著、无显著意义、不良意义)。
在研究期间,共纳入1711例患者(平均年龄:71.2岁,男性占54.1%),发现2149个DRP(每位患者1.26个DRP)。药师对所有发现的DRP都进行了干预。最常见的DRP是超治疗剂量(19.3%),其次是未治疗指征(18.1%)。导致DRP的最常见药物分类是“全身用抗感染药”(25.1%),其次是“消化道及代谢药”(19.9%)。大多数药师干预措施(99.6%)被评为“有些显著”或更显著,其中1.1%被评为“极其显著”,没有被评为“不良意义”的。
我们的结果表明,在日本,与其他国家一样,临床药师通过药物治疗回顾发现并解决住院患者的DRP。我们的研究结果还表明,临床药师对患者护理有积极影响,并表明需要他们的参与。